These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

896 related items for PubMed ID: 14529770

  • 1. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
    Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU.
    Int J Radiat Oncol Biol Phys; 2003 Nov 01; 57(3):665-72. PubMed ID: 14529770
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N.
    Urology; 2004 Sep 01; 64(3):488-93. PubMed ID: 15351577
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
    Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL.
    Lancet Oncol; 2013 Aug 01; 14(9):863-72. PubMed ID: 23823157
    [Abstract] [Full Text] [Related]

  • 6. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
    Zapatero A, Pinar B, Arellano R, López M, Marín A, Jiménez U, Pérez Torrubia A.
    Arch Esp Urol; 1997 Jun 01; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
    [Abstract] [Full Text] [Related]

  • 7. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.
    Kaufman DS, Winter KA, Shipley WU, Heney NM, Chetner MP, Souhami L, Zlotecki RA, Sause WT, True LD.
    Oncologist; 2000 Jun 01; 5(6):471-6. PubMed ID: 11110598
    [Abstract] [Full Text] [Related]

  • 8. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
    Gamal El-Deen HS.
    J Egypt Natl Canc Inst; 2007 Jun 01; 19(2):133-46. PubMed ID: 19034344
    [Abstract] [Full Text] [Related]

  • 9. Bladder preservation by combined modality therapy for invasive bladder cancer.
    Kachnic LA, Kaufman DS, Heney NM, Althausen AF, Griffin PP, Zietman AL, Shipley WU.
    J Clin Oncol; 1997 Mar 01; 15(3):1022-9. PubMed ID: 9060542
    [Abstract] [Full Text] [Related]

  • 10. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
    Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, True L, Shipley W.
    J Clin Oncol; 1996 Jan 01; 14(1):119-26. PubMed ID: 8558186
    [Abstract] [Full Text] [Related]

  • 11. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM, Khalil S, Salem EA, ElAdl M, Nawar N, Zaiton F.
    BJU Int; 2011 May 01; 107(10):1605-10. PubMed ID: 20825396
    [Abstract] [Full Text] [Related]

  • 12. Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group study.
    Einstein AB, Wolf M, Halliday KR, Miller GJ, Hafermann M, Lowe BA, Meyers FJ, Leimert JT, Crawford ED.
    Urology; 1996 May 01; 47(5):652-7. PubMed ID: 8650861
    [Abstract] [Full Text] [Related]

  • 13. Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer.
    Cobo M, Delgado R, Gil S, Herruzo I, Baena V, Carabante F, Moreno P, Ruiz JL, Bretón JJ, Del Rosal JM, Fuentes C, Moreno P, García E, Villar E, Contreras J, Alés I, Benavides M.
    Clin Transl Oncol; 2006 Dec 01; 8(12):903-11. PubMed ID: 17169764
    [Abstract] [Full Text] [Related]

  • 14. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study.
    Fellin G, Graffer U, Bolner A, Ambrosini G, Caffo O, Luciani L.
    Br J Urol; 1997 Jul 01; 80(1):44-9. PubMed ID: 9240179
    [Abstract] [Full Text] [Related]

  • 15. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution.
    Peyromaure M, Slama J, Beuzeboc P, Ponvert D, Debré B, Zerbib M.
    Urology; 2004 Jan 01; 63(1):73-7. PubMed ID: 14751352
    [Abstract] [Full Text] [Related]

  • 16. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.
    Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, Donnelly BJ, Venner PM, Perez CA, Murray KJ, Doggett RS, True LD.
    J Clin Oncol; 1998 Nov 01; 16(11):3576-83. PubMed ID: 9817278
    [Abstract] [Full Text] [Related]

  • 17. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
    Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ, Toonkel LM, Zietman AL, Tanguay S, Sandler HM.
    Urology; 2009 Apr 01; 73(4):833-7. PubMed ID: 19100600
    [Abstract] [Full Text] [Related]

  • 18. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy.
    Prout GR, Shipley WU, Kaufman DS, Heney NM, Griffin PP, Althausen AF, Bassil B, Nocks BN, Parkhurst EC, Young HH.
    J Urol; 1990 Nov 01; 144(5):1128-34; discussion 1134-6. PubMed ID: 2122007
    [Abstract] [Full Text] [Related]

  • 19. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.
    Chen WC, Liaw CC, Chuang CK, Chen MF, Chen CS, Lin PY, Chang PL, Chu SH, Wu CT, Hong JH.
    Int J Radiat Oncol Biol Phys; 2003 Jul 01; 56(3):726-33. PubMed ID: 12788178
    [Abstract] [Full Text] [Related]

  • 20. A pilot study of chemotherapy alternating with twice-a-day accelerated radiation therapy as an alternative to cystectomy in muscle infiltrating (stages T2 and T3) cancer of the bladder: preliminary results.
    Vikram B, Malamud S, Silverman P, Hecht H, Grabstald H.
    J Urol; 1994 Mar 01; 151(3):602-4. PubMed ID: 8308967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.